| 查看: 475 | 回复: 2 | |||
2010020170金虫 (小有名气)
|
[交流]
【求助】氯雷他定片 国外标准 已有2人参与
|
| 有谁知道 氯雷他定片的国外标准 我不知道在哪可以查到 谢谢 |
回复此楼» 猜你喜欢
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有223人回复
-
WoS一区Frontiers in Genome Editing基因编辑方法与应用方向专题邀稿（影响因子4.9）
已经有0人回复
-
请问怎么才能在有羧基存在的情况下，只给酚羟基上甲基
已经有4人回复
-
跪求一支AAV293细胞
已经有1人回复
-
参比制剂，自己做的PK数据与IF资料报道的数据相差很大
已经有2人回复
-
祈求中本子
已经有0人回复
-
各位大佬，H口面上什么时候会评？？？
已经有30人回复
-
2026年山东大学海洋学院生物与医药博士招生-李霞课题组
已经有0人回复
-
博士研究生招生
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 关于现阶段国内外污水处理厂中污泥脱水絮凝剂的使用
已经有8人回复
- 有关标准曲线准确度、精密度和重复性实验的问题
已经有7人回复
- 合作项目国外有语言培训，是否可以不参加暑期小语种培训
已经有9人回复
- 大家在国外读博期间出门旅游多么？
已经有31人回复
- 关于联合培养拿国内外两个学位的求助！！！！！！
已经有30人回复
- 如何查找国外环保标准
已经有6人回复
- 【专题】中国锂电池产业策略：跟踪国外先进技术，制定国内统一标准强化知识产权保护
已经有18人回复
★ ★ ★
小木虫(金币+0.5):给个红包，谢谢回帖交流
koria0727(金币+2):谢谢提供。 2011-01-15 16:36:11
小木虫(金币+0.5):给个红包，谢谢回帖交流
koria0727(金币+2):谢谢提供。 2011-01-15 16:36:11
|
USP32-NF27收载过。 Loratadine Tablets » Loratadine Tablets contain not less than 90.0 percent and not more than 110.0 percent of the labeled amount of loratadine (C22H23ClN2O2). Packaging and storage— Preserve in tight containers, and store between 2 and 30. Protect from excessive moisture if packaged in blisters. USP Reference standards 11— USP Loratadine RS . Identification— A: Thin-Layer Chromatographic Identification Test 201— Test solution— Transfer an accurately weighed quantity of Tablets, equivalent to about 20 mg of loratadine, to a centrifuge tube. Add 5.0 mL of a mixture of chloroform and methanol (1:1), rotate for 30 minutes, and centrifuge. Standard solution— Dissolve an accurately weighed quantity of about 20 mg of USP Loratadine RS in 5 mL of a mixture of chloroform and methanol (1:1), and mix. Application volume: 5 µL. Developing solvent system: ethyl ether and diethylamine (40:1), in a paper-lined tank. B: The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay. Dissolution 711— Medium: 0.1 N hydrochloric acid; 900 mL. Apparatus 2: 50 rpm. Time: 60 minutes. Procedure— Determine the amount of C22H23ClN2O2 dissolved from UV absorption at the wavelength of maximum absorbance at about 280 nm on filtered portions of the solution under test, suitably diluted with Dissolution Medium, if necessary, in comparison with a Standard solution having a known concentration of USP Loratadine RS in the same Medium. Tolerances— Not less than 80% (Q) of the labeled amount of C22H23ClN2O2 is dissolved in 60 minutes. Uniformity of dosage units 905: meet the requirements. Related compounds— 0.01 M Dibasic potassium phosphate, 0.6 M Dibasic potassium phosphate, Mobile phase, 0.05 N Hydrochloric acid, and Diluent— Proceed as directed in the Assay under Loratadine. Standard stock solution— Prepare as directed for Standard preparation in the Assay under Loratadine. Standard solution— Pipet 5.0 mL of the Standard stock solution into a 100-mL volumetric flask, and dilute with Diluent to volume. Dilute quantitatively, and stepwise if necessary, with Diluent to obtain a solution having a known concentration of about 0.8 µg per mL. Test solution— Use the Assay preparation. Chromatographic system (see Chromatography 621)— The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 15-cm column that contains 5-µm packing L7. The flow rate is about 1 mL per minute. Chromatograph the Test solution, and record the peak areas as directed for Procedure: the relative retention times are about 0.79 for 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl and 1.0 for loratadine. Chromatograph the Standard solution, and record the peak areas of the main peak as directed for Procedure: the relative standard deviation for replicate injections is not more than 4.0%. Procedure— Separately inject equal volumes (about 50 µL) of the Test solution and the Standard solution into the chromatograph, record the chromatograms, and measure all of the peak area responses in the Test solution and the peak area of the main peak in the Standard solution. Calculate the percentage of each impurity in the portion of Tablets taken by the formula: 2500(C/L)(ri / rS) in which C is the concentration, in mg per mL, of USP Loratadine RS in the Standard solution; L is the labeled quantity, in mg, of loratadine in each Tablet taken; ri is the peak area response for each impurity in the Test solution; and rS is the peak area response of loratadine in the Standard solution: not more than 0.2% of 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl is found; not more than 0.1% of any other individual impurity is found; and the sum of all impurities, other than 4-(8-chloro-11-fluoro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)-1-piperidinecarboxylate ethyl, is not more than 0.1%. Assay— 0.01 M Dibasic potassium phosphate, 0.6 M Dibasic potassium phosphate, Mobile phase, 0.05 N Hydrochloric acid, Diluent, and Standard preparation— Proceed as directed in the Assay under Loratadine. Assay preparation— Transfer 10 Tablets into a 250-mL volumetric flask, add 100 mL of 0.05 N Hydrochloric acid, and shake for 40 minutes or until the Tablets are completely disintegrated. Add 75 mL of a mixture of methanol and acetonitrile (1:1), and mix. Add 20 mL of 0.6 M Dibasic potassium phosphate, and mix for 5 minutes. Dilute with a mixture of methanol and acetonitrile (1:1) to volume, and mix. Chromatographic system (see Chromatography 621)— Prepare as directed in the Assay under Loratadine. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the capacity factor, k¢, is not less than 3.5; the tailing factor is not more than 1.7; and the relative standard deviation for replicate injections is not more than 2.0%. Procedure— Separately inject equal volumes (about 15 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the peak response for the major peaks. Calculate the quantity, in mg, of loratadine (C22H23ClN2O2) in the portion of Tablets taken by the formula: 250C(rU / rS) in which C is the concentration, in mg per mL, of USP Loratadine RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively. Auxiliary Information— Please check for your question in the FAQs before contacting USP. Topic/Question Contact Expert Committee Monograph Daniel K. Bempong, Ph.D. Senior Scientist 1-301-816-8143 (MDPS05) Monograph Development-Pulmonary and Steroids Reference Standards Lili Wang, Technical Services Scientist 1-301-816-8129 RSTech@usp.org 711 Margareth R.C. Marques, Ph.D. Senior Scientist 1-301-816-8106 (BPC05) Biopharmaceutics05 USP32–NF27 Page 2808 Pharmacopeial Forum: Volume No. 29(4) Page 1045 Chromatographic Column— LORATADINE TABLETS Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27. |
2楼2011-01-15 16:16:03
2010020170
金虫 (小有名气)
- 应助: 0 (幼儿园)
- 金币: 1093.4
- 散金: 15
- 红花: 1
- 帖子: 103
- 在线: 29.1小时
- 虫号: 1183959
- 注册: 2011-01-05
- 性别: MM
- 专业: 药剂学
3楼2011-01-16 13:04:49
